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Large populations across sub-Saharan Africa remain at risk of devastating acute bacterial meningitis epidemics and endemic 
disease. Meningitis surveillance is a cornerstone of disease control, essential for describing temporal changes in disease epide-
miology, the rapid detection of outbreaks, guiding vaccine introduction and monitoring vaccine impact. However, meningitis 
surveillance in most African countries is weak, undermined by parallel surveillance systems with little to no synergy and lim-
ited laboratory capacity. African countries need to implement comprehensive meningitis surveillance systems to adapt to the rapidly 
changing disease trends and vaccine landscapes. The World Health Organization and partners have developed a new investment 
case to restructure vaccine-preventable disease surveillance. With this new structure, countries will establish comprehensive and 
sustainable meningitis surveillance systems integrated with greater harmonization between population-based and sentinel surveil-
lance systems. There will also be stronger linkage with existing surveillance systems for vaccine-preventable diseases, such as polio, 
measles, yellow fever, and rotavirus, as well as with other epidemic-prone diseases to leverage their infrastructure, transport systems, 
equipment, human resources and funding. The implementation of these concepts is currently being piloted in a few countries in 
sub-Saharan Africa with support from the World Health Organization and other partners. African countries need to take urgent 
action to improve synergies and coordination between different surveillance systems to set joint priorities that will inform action to 
control devastating acute bacterial meningitis effectively.
Keywords.  Surveillance; Acute bacterial meningitis; Sub-Saharan Africa; African meningitis belt; Streptococcus pneumoniae; 
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Meningitis is an inflammatory disease of the meninges, the 
membranous covering of the brain and spinal cord. Some of 
the most severe forms of the disease are caused by bacteria [1]. 
Acute bacterial meningitis (ABM) can kill within hours of dis-
ease onset and leave survivors with lifelong disabilities [2, 3]. 
The global estimates of meningitis stand at 2.8 million cases and 
approximately 300 000 deaths every year [4]. The African “men-
ingitis belt” is a region spanning 26 contiguous countries, with 
an estimated 400 million people at risk of epidemic meningitis 
primarily caused by Neisseria meningitidis (the meningococcus) 
and Streptococcus pneumoniae (the pneumococcus) [5].
ROLLOUT OF CONJUGATE VACCINES IN AFRICA
Conjugate vaccines that provide protection against ABM 
caused by N.  meningitidis serogroup A  (NmA), Haemophilus 
influenzae type b (Hib), and the pneumococcus have been 
rolled out across African countries [4, 6, 7]. To date, 39 of 47 
countries in the World Health Organization (WHO) Regional 
Office for Africa (WHO/AFRO) have introduced the 10- or 
13-valent formulations of the pneumococcal conjugate vaccine 
(PCV10 or PCV13) into their infant immunization programs 
[8]. The Hib conjugate vaccine has been introduced in all coun-
tries in WHO/AFRO as part of the pentavalent infant immuni-
zation vaccine over the last 20 years [6].
The WHO/AFRO Strategic Plan for Immunization 2014–2020 
set 2 key objectives related to meningococcal meningitis con-
trol [9]: (1) rollout of meningococcal A protein–polysaccharide 
conjugate vaccine (MenAfriVac) campaigns in all 26 countries 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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within the African meningitis belt and (2) introduction of 
MenAfriVac in the Expanded Programme on Immunisation 
(EPI) of at least 16 of the 26 countries in the African menin-
gitis belt [10]. Between 2010 and 2018, MenAfriVac was rolled 
out through mass vaccination campaigns targeting individuals 
1–29 years old across 24 of the 26 African meningitis belt coun-
tries [7]. To maintain high levels of herd immunity and sustain 
control of NmA, WHO recommends that countries that have 
conducted campaigns include MenAfriVac in their EPI. As of 
April 2021, a total of 12 of the 26 African meningitis belt coun-
tries had introduced MenAfriVac into their EPI, and 3 more 
countries (Togo, Benin, and Guinea Bissau) have planned intro-
ductions in 2021.
Group B Streptococcus (GBS) is an important cause of menin-
gitis and sepsis in children <3 months of age [11]. As such, the 
development of GBS vaccines for maternal immunization has 
been prioritized by WHO, and a number of GBS vaccines are 
currently under development and at various stages of clinical 
trials [12].
THE IMPORTANCE OF MENINGITIS SURVEILLANCE
Meningitis surveillance provides health-related data to inform 
vaccination programs and is useful for monitoring the impact 
of public health practice. Effective meningitis surveillance en-
tails systematic and continuous collection and interrogation of 
data to; (1) identify priority pathogens and populations for vac-
cination, (2) guide introduction of new vaccines, (3) detect out-
breaks, (4) describe changes in disease epidemiology over time, 
including the impact of vaccination, (5) monitor antimicrobial 
resistance, and (6) describe sequelae and long-term disability 
among meningitis survivors [9].
Disease surveillance is one of the 5 pillars in the WHO road 
map to defeating meningitis by 2030 [13]. The importance of 
surveillance is emphasized by both the Addis Declaration on 
Immunisation (2012) endorsed by heads of state at the 28th 
African Union Summit, and the Immunisation Agenda 2030, 
endorsed by the World Health Assembly in 2020 [14]. The need 
for comprehensive and robust meningitis surveillance sys-
tems is great in Africa. The continent is currently faced with 
the emergence of meningococcal serogroup C, W, and X strains 
with epidemic potential [15–18], which threaten the success 
of meningococcal meningitis control achieved through the 
MenAfriVac programs [15–18]. 
Currently available polyvalent meningococcal vaccines 
(comprising serogroups A, C, Y, and W) are not affordable, and 
their use in Africa has been restricted to reactive vaccination 
campaigns [19]. A  pentavalent meningococcal conjugate vac-
cine targeting serogroups A, C, Y, W, and X is in the pipeline; 
however, data from surveillance systems are needed to guide 
vaccine strategy and implementation once the vaccine be-
comes available [20]. Robust surveillance data are also required 
to monitor the success of the immunization programs and 
establish whether herd immunity protects unvaccinated popu-
lations. There also remains a significant burden of epidemic 
meningitis caused by serotype 1 pneumococcus, which is cov-
ered by both PCV10 and PCV13. Therefore, there are questions 
around optimal PCV scheduling and the long-term benefits of 
a booster dose for enhancing herd protection and accelerating 
control of serotype 1 and other PCV serotypes, particularly in 
outbreak-prone regions [21]. For GBS, accurate data on the 
disease burden and circulating serotypes are needed to inform 
vaccine development and support the rollout of effective vac-
cines once they become available [12]. Addressing these critical 
questions around optimal vaccination strategy and scheduling 
is largely dependent upon data generated through effective 
surveillance.
CURRENT MENINGITIS SURVEILLANCE SYSTEMS 
AND THEIR LIMITATIONS
Although sub-Saharan Africa has the largest burden of men-
ingitis globally, most countries have meningitis surveillance 
systems that are weak, poorly integrated, and rely heavily on ex-
ternal financing and technical assistance [9]. Of the 47 WHO/
AFRO member states, 39 allocate less than 10% of their rou-
tine immunization expenditure to surveillance activities, with 
an even smaller proportion spent on meningitis surveillance 
specifically [9]. This challenge is compounded by countries 
running several meningitis surveillance systems in parallel, 
further stretching the already limited resources available [9, 
22]. Surveillance efforts are further undermined by often in-
termittent or incomplete laboratory identification of patho-
gens. Although there are a few exceptions [23], there is limited 
intracountry and intercountry synergy in meningitis surveil-
lance programs, despite the potential benefits of regional coop-
eration in tackling meningitis epidemics and endemic disease.
The Integrated Disease Surveillance and Response (IDSR) 
system was established in 1998 by WHO/AFRO in partnership 
with technical partners. This system uses standardized tools to 
collect aggregated data for multiple diseases and was adopted 
by all AFRO member states [24]. The Enhanced Meningitis 
Surveillance system was built on the IDSR framework and im-
plemented in 24 African meningitis belt countries in 2004 to 
enable early detection, confirmation, and response to menin-
gitis outbreaks [25]; the system collects clinical, demographic, 
and laboratory data from suspected meningitis cases, which are 
reported weekly.
In 2001, the WHO-supported African Paediatric Bacterial 
Meningitis (PBM) surveillance network was established [22]. 
The PBM network supports hospital-based sentinel surveil-
lance of meningitis among children less than 5 years old across 
33 countries in WHO/AFRO. In 2008, the PBM Network be-
came part of the global invasive bacterial vaccine-preventable 
disease (IB-VPD) network. The IB-VPD surveillance plat-
form collects data on the epidemiology of invasive bacterial 
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vaccine-preventable diseases (VPDs) and evaluates vaccine im-
pact [26]. The PBM and IB-VPD networks have made signifi-
cant efforts to standardize data collection as well as clinical and 
laboratory protocols in participating states.
Leveraging the Enhanced Meningitis Surveillance system, the 
MenAfriNet consortium successfully established case-based men-
ingitis surveillance in 5 meningitis belt countries (Burkina Faso, 
Chad, Mali, Niger, and Togo) in 2014 [27]. Case-based surveillance 
in these countries provided data on the epidemiologic trends of 
meningitis following the implementation of MenAfriVac and PCV. 
In the next phase of MenAfriNet, the focus is on further strength-
ening case-based surveillance in Burkina Faso and Niger to sup-
port introduction of the pentavalent meningococcal vaccine, with 
regional support for other countries in the African meningitis belt, 
including Chad, Mali, and Togo [23].
Other types of meningitis surveillance operational in 
the WHO/AFRO region are the notifiable disease surveillance 
system and other laboratory-based surveillance systems. South 
Africa, for instance, which did not implement the IDSR system, 
uses the notifiable disease surveillance system and the Group 
for Enteric, Respiratory and Meningeal Disease Surveillance in 
South Africa (GERMS-SA)  to track bacterial meningitis [28, 
29].
Although data collected through all these surveillance 
programs were used to support the implementation of vac-
cines and monitor vaccine impact, there remain large gaps in 
the understanding of meningitis across most African countries, 
particularly beyond early childhood and the 3 main bacterial 
pathogens (pneumococcus, meningococcus and H. influenzae) 
[30].
THE CASE FOR AN INTEGRATED MENINGITIS 
SURVEILLANCE SYSTEM
The rapidly changing epidemiology of VPDs and the evolving 
vaccine landscape coupled with multiple meningococcal out-
breaks caused by non-A serogroups call for urgent action to 
strengthen meningitis surveillance in sub-Saharan Africa. The 
PBM and Global IB-VPD surveillance networks leveraged 
funding and resources through Gavi, the Vaccine Alliance, and 
the Global Polio Eradication Initiative; however, the funding 
available is declining [9]. The lack of harmonization in the cur-
rent meningitis surveillance programs within and across coun-
tries means that there are significant redundancies and cost 
inefficiencies.
Integration of existing meningitis surveillance systems will 
be key to achieving sustainable, comprehensive systems that 
are synergistic, efficient, and cost-effective. As such, WHO re-
commends the integration of PBM, enhanced, and case-based 
meningitis surveillance programs that currently run in parallel 
in most countries in WHO/AFRO. Furthermore, meningitis 
surveillance should not be in a separate silo; instead, it should 
be integrated into the VPD surveillance systems supported by 
strong laboratories with the capacity to detect cases and out-
breaks, and generate useable information to guide outbreak 
preparedness and responses, immunization, program optimiza-
tion, and vaccine policy as outlined in recent WHO guidance 
documents [9, 31].
The 6 key components for efficient, comprehensive and inte-
grated surveillance of VPDs, as proposed in the WHO/AFRO 
investment case are as follows: 
1. Governance and management: The establishment of 
country-owned and country-funded surveillance systems in-
tegrated within national VPD surveillance. This will entail 
greater commitment, ownership and leadership with account-
ability from the member states at the supranational, national, 
subnational, and district levels.
2. Standards for surveillance (harmonization): Setting up 
standardized guidelines and practices for meningitis sur-
veillance and other VPDs. High-quality management will be 
needed to monitor and evaluate compliance with guidelines, 
standard case definitions, procedures, and data collection tools.
3. Laboratory capacity and networks: Leveraging well-es-
tablished laboratory networks for other VPDs, such as mea-
sles, yellow fever, rotavirus, and polio as much as possible. 
These networks seek to ensure that laboratories are adequately 
equipped, have staff trained according to standardized proto-
cols, maintain quality controls and have accreditations. This is 
particularly important for meningitis caused by the pneumo-
coccus, meningococcus, H. influenzae and GBS, for which pol-
ymerase chain reaction (PCR)–based serotyping/serogrouping 
capacity is essential.
4. Specimen management: Maintaining high quality stand-
ards for the collection, storage and transportation of cerebro-
spinal fluid (CSF) specimens, according to standard operating 
procedures. This requires the use of the appropriate specimen 
collection tools (eg, lumbar puncture kits), storage media (eg, 
Trans-Isolate  (TI) medium), and preservation of specimens 
for molecular analysis. Establishing efficient supply chains for 
specimen management is critical, especially during meningitis 
epidemics.
5. Detection and response: Drawing up and updating 
national epidemic preparedness plans for the rapid detection 
and confirmation of meningitis outbreaks. Preparedness plans 
should include risk-mapping, assessment and mitigation plans, 
staff mobilization, community awareness, communication 
strategies, and evaluation of emergency response performance. 
These plans should be adaptive to unexpected changes and re-
viewed regularly. 
6. Surveillance process, data management and analysis, and 
reporting: Effective and timely responses depend on high-
quality information (accurate and complete) to be collected 
at all stages, including case detection, notification, investiga-
tion, and confirmation. Health facilities are the primary case-
reporting sites; as such, training and sensitization programs 
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need to be inclusive, involving health workers, disease surveil-
lance officers, and the communities they serve.
THE CASE FOR EFFECTIVE USE OF SURVEILLANCE 
DATA TO INFORM EPI DECISIONS
Nearly all countries in WHO/AFRO that have introduced 
PCV, MenAfriVac and Hib conjugate vaccinee have done 
so with financial support from Gavi, The Vaccine Alliance. 
In preparation for the pentavalent meningococcal vaccine, 
which is likely to become available in the next 2–4 years, the 
Gavi board approved the expansion of the existing meningo-
coccal program. However, this approval will be contingent 
on an evidence-based technical recommendation on vacci-
nation strategy to identify the target age groups, duration of 
protection, and priority communities. Hence, compared with 
the current Gavi vaccine-support model for MenAfriVac, 
Gavi-supported implementation of the multivalent meningo-
coccal vaccine in routine immunization and campaigns will 
be more narrowly targeted in terms of both geographic areas 
and age groups covered. It is expected that the recommended 
vaccination strategy will vary among countries in the African 
meningitis belt.
Member states will need to consider these approval require-
ments as they prepare for the rollout of the pentavalent me-
ningococcal vaccine. Countries will need to generate disease 
burden data through surveillance, including serogroups and 
genotypes of the causative pathogens. These data will be nec-
essary to identify high-priority populations and age groups as 
well as guide vaccination strategy (mass vaccination campaigns, 
routine vaccination, or reactive vaccination).
PILOTING MENINGITIS SURVEILLANCE 
INTEGRATION
At the 17th Annual Meeting on Surveillance, Preparedness and 
Response to Meningitis Outbreaks in Africa and the seventh 
meeting of MenAfriNet Partners, held virtually in December 
2020, the feasibility of integrating meningitis surveillance and 
adapting recent technologies to improve surveillance in Africa 
was discussed. Several countries expressed interest in exploring 
the possibility of expanding meningitis surveillance to collect 
data on all ages using a “one meningitis approach”. These con-
cepts are being piloted in Ghana, Togo, Nigeria, Mozambique, 
Burundi, and Tanzania with support from WHO and partners. 
The US Centers for Disease Control and Prevention and Takeda 
Pharmaceutical Company are also funding pilots of compre-
hensive surveillance approaches in 14 countries in the WHO/
AFRO Region.
During this meeting, Mozambique shared experiences and 
outlined ongoing efforts to expand and integrate meningitis 
surveillance. With the support of Gavi, Mozambique introduced 
PCV10 into its EPI in April 2013 [32]. PCV10 was replaced by 
PCV13 nationwide in May 2019, with a phased rollout that 
started in December 2017 in the north of the country. Instituto 
Nacional de Saúde (INS) has been conducting surveillance for 
meningitis since 2013 at 3 sentinel sites. In 2018 a surveillance 
evaluation conducted by the Centers for Disease Control and 
Prevention and WHO/AFRO in collaboration with INS revealed 
several gaps in case identification, specimen collection, storage, 
and transport. Therefore, in November 2019, Mozambique INS 
embarked on the phased expansion of its meningitis surveil-
lance system to include adults as part of integrated surveillance.
NEW TECHNOLOGIES AND INNOVATIONS
Improving meningitis diagnosis is one of the key priorities 
in the WHO road map for defeating meningitis by 2030 [14]. 
Implementation of new diagnostic innovations can greatly im-
prove meningitis surveillance in WHO/AFRO, where most la-
boratories have limited microbiologic capacity.
Molecular tools offer additional diagnostic power alongside 
traditional culture methods in that they are rapid, highly sen-
sitive, and specific. Molecular tools can detect pathogens in 
archived specimens and patients who have received prior anti-
biotic treatment, are high throughput, and can be used to type 
pathogens. Although quantitative PCR (qPCR) is used to detect 
pathogens in the Africa PBM surveillance [22], MenAfriNet 
surveillance activities [27] and meningococcal carriage surveys 
in the African meningitis belt [33], these tools are not yet widely 
used for meningitis diagnosis across WHO/AFRO. QPCR is 
performed routinely on CSF and/or blood collected from sus-
pected cases of meningitis in many high-income countries, in-
cluding the United Kingdom, and has been shown to increase 
case confirmation [34]. The adoption of molecular tools for 
ABM detection would circumvent some of the challenges posed 
by limited microbiologic capacity for CSF and blood cultures. 
Improving access to qPCR-based meningitis diagnostic tools 
should be an important part of efforts to improve VPD surveil-
lance in WHO/AFRO Region.
The TaqMan Array Card (TAC) is a qPCR-based detection 
platform that is useful for the simultaneous and accurate de-
tection of multiple bacterial, viral, protozoan, and fungal 
pathogens, using very small amounts of clinical specimens. 
Kwambana-Adams et al [30] demonstrated the utility of a TAC 
platform that significantly enhanced the diagnosis of meningitis 
pathogens compared to conventional molecular tools among 
West African children <5 years of age with suspected menin-
gitis, who were identified through the PBM network.
Rapid diagnostic tests through immunochromatography and 
latex agglutination testing are simple to use, can provide results 
in <2 hours, and have the potential to enhance meningitis sur-
veillance in WHO/AFRO. Although meningitis rapid diagnostic 
tests have been developed, most, including currently available 
latex agglutination tests, have been shown to have limited utility 
and reliability for meningitis diagnosis in low-resource settings 
[35]. However, new rapid tests are showing promise and may 
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become widely available in the coming years. If that happens, 
they could play a very important role in improving meningo-
coccal surveillance in the WHO/AFRO.
Pathogen whole-genome sequencing (WGS) is becoming in-
creasingly accessible and can be used in combination with epi-
demiologic data to type strains, infer the spread of antimicrobial 
resistance genes, and identify transmission networks, particu-
larly in outbreak scenarios. WGS was used to demonstrate that 
the NmC strain that caused the most recent large meningitis 
outbreaks in Niger [16] and Nigeria [15] belonged to the se-
quence type 10217. This outbreak NmC strain had emerged 
from a benign commensal organism that acquired capsule and 
virulence genes that confer epidemic potential [18].
WGS has relied on the isolation of viable bacteria, so that 
large amounts of DNA can be purified. However, the major 
challenge to this approach is that bacterial culture and storage 
capacity tends to be limited, especially in outbreak settings in 
Africa. Metagenomic approaches have been used to characterize 
meningitis during outbreaks [36–38] and during surveillance 
[39]. In the future and with further validation, meningitis sur-
veillance could include the use of portable real-time sequencing 
platforms such as the Oxford Nanopore Technologies MinION 
which can be used to sequence nucleic acids from CSF [40] at 
the bedside, even in remote areas. These innovative technolo-
gies in surveillance programs will allow real-time detection, 
serotyping/serogrouping, genotyping, and antimicrobial re-
sistance prediction of meningitis pathogens, which could be a 
game changer for outbreak responses in Africa.
Innovations in web-based data collection and sharing tools 
mean that data can be shared more quickly and securely. The use 
of platforms that allow interrogation and management of data 
collection in real time can enhance overall data quality (com-
pleteness and accuracy), which is at the core of any successful 
surveillance system. One such innovation which is being explored 
for meningitis sentinel surveillance is the Research Electronic 
Data Capture (REDCap) data collection instrument offered by 
the Johns Hopkins Biostatistics Center [41]. The REDCap system 
is more secure than most, can be accessed from any device with 
an internet connection, and maintains audit trails of all activity, 
and data collected can be stored independently by each stake-
holder. Other systems, including District Health Information 
Software 2 and the Surveillance Outbreak Response Management 
and Analysis System have similar features. These data collection 
instruments can enhance the performance of meningitis surveil-
lance programs, which often involve several stakeholders at var-
ious levels with data sharing in multiple directions.
CARRIAGE SURVEYS AS COMPLEMENTARY TO 
ROUTINE SURVEILLANCE
Upper airway carriage of the pneumococcus and meningo-
coccus is a prerequisite for disease and onward transmission 
across individuals [42]. Carriage surveys can be useful tools to 
measure vaccine effectiveness in clinical trials, monitor vaccine 
impact on circulating strains after implementation, and provide 
information on pathogen circulation, especially where the dis-
ease burden is difficult to measure [43].
The African Meningococcal Carriage Consortium 
(MenAfriCar)  conducted a series of sequential meningococcal 
carriage surveys in urban and rural populations across 7 coun-
tries in the African meningitis belt, before and after the rollout 
of MenAfriVac vaccination campaigns [44, 45]. Although me-
ningococcal carriage prevalence was 3.4%, relatively lower than 
in high-income countries [46], this study showed complex and 
highly dynamic carriage patterns. The MenAfriCar study showed 
a 98% decline in the carriage prevalence of NmA, comparable to 
the 94% reduction in NmA disease in vaccinated communities 
[45]. Carriage surveys were also used to guide Hib implementa-
tion in The Gambia and have been used to monitor vaccine im-
pact on circulating strains after implementation [47, 48].
In addition to monitoring vaccine impact, carriage surveys 
can also be used to identify risk factors for exposure and res-
ervoirs of outbreak strains [49, 50]. For instance, a carriage 
survey conducted during a meningococcal serogroup C (NmC) 
outbreak among university campus residents in the United 
Kingdom [51], revealed that the campus bars were linked to 
the carriage and transmission of the outbreak NmC strain [51]. 
Carriage surveys are therefore also useful to inform prevention 
and control strategies during ABM outbreaks.
Carriage surveys can also be useful for the isolation, anti-
microbial susceptibility testing, and genomic sequencing of cir-
culating strains in situations where microbiologic culture from 
invasive sites (CSF and blood) is difficult or not possible. As 
WHO/AFRO member states move toward integrated menin-
gitis surveillance, carriage surveys could be employed to com-
plement disease surveillance activities.
CONCLUSIONS
Effective meningitis surveillance is the cornerstone of disease 
control and elimination. As such, it is one of the 5 overlapping 
pillars to defeat meningitis, as outlined in the WHO road map 
[13]. With increasing pressures from emerging infections and 
the implementation of new vaccines, the need for WHO/AFRO 
countries to establish effective meningitis surveillance sys-
tems has never been greater. Here, we have made the case that 
WHO/AFRO member states need to integrate the current men-
ingitis surveillance systems to attain and maintain high-quality 
and broad-based surveillance for meningitis. The establishment 
of country-owned, comprehensive and sustainable meningitis 
surveillance systems hinges on effective integration and harmo-
nization of meningitis surveillance within and across regions. 
Countries need to put plans into action to improve synergies 
and coordination between surveillance and immunization 
programs and to set joint priorities informing action to effec-
tively control meningitis.
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